Special Issue "Cancer Proteomics"
A special issue of Proteomes (ISSN 2227-7382).
Deadline for manuscript submissions: closed (31 March 2017).
Prof. Dr. Karl-Friedrich Becker
Institute of Pathology, Technische Universität München, München, Germany
Website | E-Mail
Interests: quantitative (phospho)protein analysis of clinical tissue samples; development and validation of molecular biomarkers; improvement of tissue quality for diagnosis and research; intratumoral heterogeneity of human cancers; tissue proteomics; reverse phase protein array; protein biomarkers in cancer tissues; diagnosis; therapy; pathology; tumor heterogeneity; preanalytics; standardization; personalized medicine
While human cancers evolve from benign to malignant lesions by acquiring a series of gene mutations over time, the results of gene mutations translate to dysregulation or dysfunction of proteins, which are attractive molecular biomarkers and drug targets. Proteomics technologies have much improved during the last five years. Powerful extract-based and section-based methods and their targeted and discovery-based variations are available to establish comprehensive protein profiling maps in human cancers.
One goal for clinical proteomics will be to characterize the information flow within single cells, tissues or entire organisms under normal or disease conditions. Although tissue samples will continue to be the material of choice for definitive cancer diagnosis, evaluation of treatment response and disease monitoring may be performed using less invasive samples, for example, blood samples or other body fluids, such as urine or saliva. In addition, assays that can measure protein interactions will complement current protein profiling technologies. In order to improve assay results and patient outcomes, the pre-analytical workflow for clinical proteomics needs to be standardized.
This Special Issue on cancer proteomics will highlight the opportunities and possibilities of proteomic studies in cancer research. The newest proteomics technologies in different fields of cancer biology will be reviewed and challenges for their implementation in future clinical workflows addressed.
Prof. Dr. Karl-Friedrich Becker
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Proteomes is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- post translational modifications
- tumor heterogeneity
- personalized medicine
- mass spectrometry
- MALDI Imaging
- Reverse Phase Protein Arrays